NCT05231200 Alberta Collaborative QI Strategies to Improve Outcomes of Moderate and Late Preterm Infants (ABC-QI Trial)
| NCT ID | NCT05231200 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Calgary |
| Condition | Length of Stay |
| Study Type | INTERVENTIONAL |
| Enrollment | 9,500 participants |
| Start Date | 2023-05-01 |
| Primary Completion | 2027-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 9,500 participants in total. It began in 2023-05-01 with a primary completion date of 2027-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The ABC-QI Trial aims to implement collaborative quality improvement (QI) strategies to standardize care for 32-36 week infants in Level 2 and 3 Neonatal intensive care units (NICUs) across the province of Alberta. The investigators want to know if using validated quality improvement methods and evidence-based care bundles will decrease the duration of hospital stay and get babies home as quickly as possible.
Eligibility Criteria
Inclusion Criteria: Preterm Infants: Infants born at 32 to 36 weeks' gestation and admitted to the participating NICUs or postpartum units. Quality Improvement Implementation Survey version 2 (QIIS-II) and semi-structured interview participants: Management staff, nurses, nurse practitioners, physicians, and allied health staff employed in participating NICUs. Exclusion Criteria: * Preterm Infants: * Major congenital anomalies or chromosomal abnormalities. * Primary admission to a surgical NICU: Alberta Children's Hospital or Stollery Children's Hospital. * Infants born in or transferred to a NICU outside Alberta. * Patients who have imposed confidentiality restrictions on accessing their health records.
Contact & Investigator
Ayman Abou Mehrem, MD
PRINCIPAL INVESTIGATOR
University of Calgary
Frequently Asked Questions
Who can join the NCT05231200 clinical trial?
This trial is open to participants of all sexes, aged 32 Weeks or older, up to 36 Weeks, studying Length of Stay. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05231200 currently recruiting?
Yes, NCT05231200 is actively recruiting participants. Contact the research team at mahesha.yatigalpotht@ucalgary.ca for enrollment information.
Where is the NCT05231200 trial being conducted?
This trial is being conducted at Calgary, Canada, Calgary, Canada, Calgary, Canada, Calgary, Canada and 8 additional locations.
Who is sponsoring the NCT05231200 clinical trial?
NCT05231200 is sponsored by University of Calgary. The principal investigator is Ayman Abou Mehrem, MD at University of Calgary. The trial plans to enroll 9,500 participants.